135 related articles for article (PubMed ID: 31822998)
1. Tectal glioma harbors high rates of KRAS G12R and concomitant KRAS and BRAF alterations.
Chiang J; Li X; Liu APY; Qaddoumi I; Acharya S; Ellison DW
Acta Neuropathol; 2020 Mar; 139(3):601-602. PubMed ID: 31822998
[No Abstract] [Full Text] [Related]
2. Novel KRAS mutation in an unusual tectal low-grade glioma.
Wulfovich S; Tucker S; Levy M; Crawford JR
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33795262
[No Abstract] [Full Text] [Related]
3. Atypical Molecular Features of Pediatric Tectal Glioma: A Single Institutional Series.
Yakir MJ; Elster JD; Paul MR; Khanna PC; Malicki DM; Levy ML; Crawford JR
J Pediatr Hematol Oncol; 2023 Apr; 45(3):e410-e414. PubMed ID: 36730386
[TBL] [Abstract][Full Text] [Related]
4. Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours.
Nguyen AT; Colin C; Nanni-Metellus I; Padovani L; Maurage CA; Varlet P; Miquel C; Uro-Coste E; Godfraind C; Lechapt-Zalcman E; Labrousse F; Gauchotte G; Silva K; Jouvet A; Figarella-Branger D;
Neuropathol Appl Neurobiol; 2015 Apr; 41(3):403-8. PubMed ID: 25389051
[No Abstract] [Full Text] [Related]
5. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
Ates O; Yalcin S
Indian J Cancer; 2019; 56(2):176-179. PubMed ID: 31062740
[TBL] [Abstract][Full Text] [Related]
6. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
7. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF
Ellison DW; Hawkins C; Jones DTW; Onar-Thomas A; Pfister SM; Reifenberger G; Louis DN
Acta Neuropathol; 2019 Apr; 137(4):683-687. PubMed ID: 30848347
[No Abstract] [Full Text] [Related]
8. KRAS and BRAF mutation status in patients with sporadic colorectal cancer: data from two different Mediterranean countries.
Symvoulakis EK; Zaravinos A; Zoras O; Spandidos DA
Int J Biol Markers; 2011; 26(4):276-7. PubMed ID: 22139644
[No Abstract] [Full Text] [Related]
9. Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma.
Raswoli M; Nobre L; Hawkins C; Bartels UK; Tabori U; Bouffet E
Pediatr Blood Cancer; 2021 Jan; 68(1):e28561. PubMed ID: 32681754
[No Abstract] [Full Text] [Related]
10. Activating BRAF G469A Missense Mutation in a Pediatric Patient With High-Grade Glioma.
Kronish A; DeNardo B; Kanach C; Lulla RR
J Neuropathol Exp Neurol; 2021 Dec; 80(12):1141-1142. PubMed ID: 34965294
[No Abstract] [Full Text] [Related]
11. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation.
Dodgshun AJ; SantaCruz N; Hwang J; Ramkissoon SH; Malkin H; Bergthold G; Manley P; Chi S; MacGregor D; Goumnerova L; Sullivan M; Ligon K; Beroukhim R; Herrington B; Kieran MW; Hansford JR; Bandopadhayay P
J Neurooncol; 2016 Jun; 128(2):293-302. PubMed ID: 26994902
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
13. Double
Deshwar A; Margonis GA; Andreatos N; Barbon C; Wang J; Buettner S; Wagner D; Sasaki K; Beer A; Løes IM; Pikoulis E; Damaskos C; Garmpis N; Kamphues K; He J; Kaczirek K; Poultsides G; Lønning PE; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
Anticancer Res; 2018 May; 38(5):2891-2895. PubMed ID: 29715113
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations.
Hong T; Yan Y; Li J; Radovanovic I; Ma X; Shao YW; Yu J; Ma Y; Zhang P; Ling F; Huang S; Zhang H; Wang Y
Brain; 2019 Jan; 142(1):23-34. PubMed ID: 30544177
[TBL] [Abstract][Full Text] [Related]
15. Mutation status and surgical selection.
Margonis GA; Kreis ME; Wolfgang CL; Weiss MJ
J Surg Oncol; 2019 Apr; 119(5):616-622. PubMed ID: 30779134
[TBL] [Abstract][Full Text] [Related]
16. To BRAF or not to BRAF: is that even a question anymore?
Horbinski C
J Neuropathol Exp Neurol; 2013 Jan; 72(1):2-7. PubMed ID: 23242278
[TBL] [Abstract][Full Text] [Related]
17. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
18. [Pilocytic astrocytoma with KRAS gene mutation: a clinicopathological analysis of two cases].
Yu TP; Zhang MX; Zhang JY; Gong J; Zhou Q; Chen N
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):477-479. PubMed ID: 38678329
[No Abstract] [Full Text] [Related]
19. An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer.
Epperla N; George B
J Gastrointest Cancer; 2016 Jun; 47(2):206-9. PubMed ID: 26018827
[No Abstract] [Full Text] [Related]
20. Frequency assessment of BRAF mutation, KRas mutation, and RASSF1A methylation in nodular goitre based on fine-needle aspiration cytology specimens Ocena częstości występowania mutacji genów BRAF, KRas oraz.
Koziołek M; Bińczak-Kuleta A; Stepaniuk M; Parczewski M; Andrysiak-Mamos E; Sieradzka A; Safranow K; Osowicz-Korolonek L; Kiedrowicz B; Kram A; Ciechanowicz A; Syrenicz A
Endokrynol Pol; 2015; 66(5):384-93. PubMed ID: 26457492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
